As Merck cans another hepatitis C project, can leader Gilead capitalize?
admin 29th September 2017 Uncategorised 0These days, hepatitis C isn’t looking like the cash cow market it once was, prompting some of those trailing behind leader Gilead to bail on their development programs. But how much will those rivals’ moves actually help the struggling drugmaker?
read more